ASH 2025 | GoBroad Healthcare Group Shines on International Academic Stage with 33 Research Presentations

Orlando, USA, Dec 6-9, 2025 – The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.

GoBroad Healthcare Group, a consistent contributor to the global hematology landscape, has previously presented Chinese research findings hundreds of times at international congresses like EHA, ASH, EBMT, and ASCO. At this year's ASH meeting, the team led or participated in 33 accepted studies, including 3 oral presentations, 29 poster presentations, and 1 published paper abstract. Their research spans key areas including CAR-T cell therapy, hematopoietic stem cell transplantation, management of pediatric and rare blood diseases, genomic profiling and precision medicine, and expanding applications for autoimmune diseases. This broad and deep portfolio demonstrates the team's long-term commitment and systematic innovation capabilities, rooted in addressing clinical problems and improving patient outcomes.

Selected Oral Presentations:

Abstract #255: Sequential BCMA and GPRC5D CAR-T cell therapy combined with an optimizing bridging regimen for Relapsed/Refractory multiple myeloma with bulky/extensive extramedullary disease: A synergistic integration approach 

First Author: Cheng Fangfang

Corresponding Author & Presenter: Zhang Yajing

Affiliation: Beijing GoBroad Borun Hospital

Abstract #672: Prospective phase I/II study of CD19-directed CAR-T therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile 

Presenter: Li Danyang;

Corresponding Author: Zhang Yajing

Affiliation: Beijing GoBroad Hospital

Abstract #1053: Impact of Hereditary Predisposition Genes to Hematologic Malignancies on Transplant Outcomes and Donor Selection 

Presenter: Li Zhihui;

Corresponding Author: Wu Tong

Affiliation: Beijing GoBroad Boren Hospital

Selected Poster Presentations:

Abstract #1568: Daratumumab and venetoclax-based combined regimen for relapsed/refractory T lymphoblastic leukemia/lymphoma

First Author: Shao Shan

Corresponding Author: Wang Chun

Affiliation: GoBroad Healthcare, Group Shanghai Zhaxin Hospital&Shanghai LiQuan Hospital

Abstract #2368: CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm open-label phase I study

First Author: Yang Fan

Corresponding Author: Hu Kai

Affiliation: Beijing GoBroad Hospital

Abstract #2370: Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

First Author: Liu Siyu

Corresponding Author: Pan Jing

Affiliation: Beijing GoBroad Hospital

Abstract #2377: The ratio of post-infusion circulating PD-1⁺ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

First Author: Yang Fan

Corresponding Author: Hu Kai

Affiliation: Beijing GoBroad Hospital

Abstract #2386: Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression: A longitudinal multi-omic analysis supporting a paradigm shift in CRS management

First Author: He Ruijie

Corresponding Author: Zhang Yajing

Affiliation: Beijing GoBroad Borun Hospital

Abstract #2427: Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants

First Author: Liao Jianyun

Corresponding Author: Li Chunfu

Affiliation: GoBroad Chunfu Hematology Research Institute

Abstract #2467: Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety

Authors: Chen Jingtao¹, Liao Jianyun², Huang Fen¹, He Lan², Wang Fang², Xia Yuqian², Li Chunfu²

Corresponding author: Liu Qifa¹

Affiliation: [1] Nanfang Hospital, Southern Medical University; [2] GoBroad Chunfu Hematology Research Institute

Abstract #2529: Pre-transplant MRD negativity predicts favourable outcomes of CAR-T therapy for paediatric relapsed and refractory acute lymphoblastic leukaemia followed by TCRαβ-depleted haplo-HSCT

First Author: Liu Huaying

Corresponding Author: Li Chunfu

Affiliation: GoBroad Chunfu Hematology Research Institute

Abstract #3367: Adverse genetic alterations and their prognostic impact in Chinese B-ALL patients with DUX4 rearrangement

First Author: Xia Xiyu, Yang Keyan

Corresponding Author: Zheng Qinlong

Affiliation: Beijing GoBroad Borun Hospital

Abstract #3526; Impact of ALK Fusion Variants and Genetic Profiles on Prognosis in Chinese Paediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma

First Authors: Li Yang, Yang Jing

Corresponding Authors: Zhang Yonghong, Zheng Qinlong

Affiliation: Beijing GoBroad Boren Hospital, Beijing Children's Hospital Affiliated to Capital Medical University, and 15 other hospitals within the CNCL Collaborative Group

Abstract #3706; Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma

First Author: Liu Rui

Corresponding Author: Hu Kai

Affiliation: Beijing GoBroad Hospital

Abstract #3708: CAR-T cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

First Author: Li Danyang

Corresponding Author: Hu Kai

Affiliation: Beijing GoBroad Hospital

Abstract #4146: SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease 

First Author: Li Su¹;

Corresponding Author: Pan Jing²;

Affiliations: [1] GoBroad Medical Group Shanghai Liquan Hospital  [2] Beijing GoBroad Hospital

Abstract #4150: Five-year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia 

First & Corresponding Author: Pan Jing;

Affiliation: Beijing GoBroad Hospital

Abstract #4169: Prolonged thrombocytopenia following diverse CAR-T cell therapies: High incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort 

First Author: Su Guo'ai;

Corresponding Author: Zhang Yajing;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #4190: TBI-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T-cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation 

First Author: Zhao Chuxian;

Corresponding Author: Wang Chun;

Affiliation: Shanghai Zhaxin Hospital/Shanghai Liquan Hospital, GoBroad Medical Group

·

Abstract #4215: Single center evaluation of TCRαβ⁺ T cell depletion using CliniMACS® Plus platform: Optimizing cell selection for hematopoietic stem cell transplantation 

First Author: Ou Rilan;

Corresponding Authors: Li Chunfu, He Yuelin;

Affiliation: GoBroad Chunfu Hematology Institute

Abstract #4274: Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: A single center in China 

First Author: Zong Sa;

Corresponding Authors: Li Chunfu, Peng Zhiyong;

Affiliation: GoBroad Chunfu Hematology Institute

Abstract #4281: Superior disease-free survival of allogeneic hematopoietic stem cell transplantation in elderly patients with hematological malignancies in complete remission by reduced-intensity or myeloablative conditioning 

First Authors: Zhao Yongqiang, Fang Fang;

Corresponding Author: Wu Tong;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #5107: A prospective non-randomized controlled study of vaseline-medicated gauze for topical management of chemotherapy-induced oral mucositis in pediatric hematology patients 

First Author: Wu Xiaoyuan;

Corresponding Author: Pan Jing;

Affiliation: Beijing GoBroad Hospital

Abstract #5314: The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma 

First Authors: Zhang Caiyan, Liu Ying;

Corresponding Authors: Zhang Yonghong, Zheng Qinlong;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #5484: Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy 

First Author: Yang Fan;

Corresponding Author: Hu Kai;

Affiliation: Beijing GoBroad Hospital

Abstract #5489: Genomic heterogeneity and prognostic implications in CAR-T-treated relapsed/refractory primary CNS lymphoma 

First Author: Cao Miaomiao;

Corresponding Author: Hu Kai;

Affiliation: Beijing GoBroad Hospital

Abstract #5933: Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies 

First Author: Lu Haiyang¹;

Corresponding Authors: Hu Xiaoxia¹, Pan Jing²;

Affiliations: [1] Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine [2] Beijing GoBroad Hospital

This study received an ASH Abstract Achievement Award.

Abstract #5934: A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure First Author: Li Su¹;

Corresponding Author: Pan Jing²;

Affiliations: [1] Shanghai Liquan Hospital, GoBroad Medical Group [2] Beijing GoBroad Hospital

Abstract #5948: Unveiling the "second wave": Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management 

First Author: Su Guo'ai;

Corresponding Author: Zhang Yajing;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #5989: Study on five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation patients — Achieving zero infection through data-driven and optimized nursing schemes 

First Authors: Wang Xiaoxia, Chen Fengying;

Corresponding Author: Wu Tong;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #5993: Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases 

First Author: Song Yanzhi;

Corresponding Author: Wu Tong;

Affiliation: Beijing GoBroad Boren Hospital

Abstract #6062: A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRαβ cell depleted HCT 

First Author: Liu Huaying;

Corresponding Author: Li Chunfu;

Affiliation: GoBroad Chunfu Hematology Institute

Published Abstract:

Abstract #7735:  A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia

 First Authors: Zhao Yongqiang, Wang Rui;

Corresponding Author: Wu Tong;

Affiliation: Beijing GoBroad Boren Hospital

Confronting shared global challenges in blood disease management, GoBroad Medical Group persistently explores safer, more effective, and accessible treatment strategies. They aim to bridge academic research and clinical practice, contributing more verifiable and scalable original Chinese solutions. Moving forward, the team will continue to collaborate deeply with global peers, fostering exploration, connection, and shared value, striving to deliver survival benefits and renewed hope to more patients with hematologic diseases.

HospitalGuide